columbamine has been researched along with Liver Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, X; Cheng, Z; Guo, P; Li, S; Lin, Z; Wang, L; Yan, H; Yan, Z; Zhao, C; Zheng, C; Zheng, L | 1 |
| Bin, W; Cao, S; Kang, N; Qiu, F; Wang, Y; Xu, P; Yan, J; Zhou, Y | 1 |
2 other study(ies) available for columbamine and Liver Neoplasms
| Article | Year |
|---|---|
Columbamine suppresses hepatocellular carcinoma cells through down-regulation of PI3K/AKT, p38 and ERK1/2 MAPK signaling pathways.
Topics: Animals; Apoptosis; Berberine Alkaloids; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Movement; Cell Proliferation; Female; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Male; MAP Kinase Signaling System; Mice; Mice, Nude; p38 Mitogen-Activated Protein Kinases; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2019 |
Berberine metabolites could induce low density lipoprotein receptor up-regulation to exert lipid-lowering effects in human hepatoma cells.
Topics: Berberine; Berberine Alkaloids; Berberis; Carcinoma, Hepatocellular; Coptis; Dose-Response Relationship, Drug; Hep G2 Cells; Humans; Hypolipidemic Agents; Lipid Metabolism; Lipoproteins, LDL; Liver Neoplasms; Plant Extracts; Receptors, LDL; RNA, Messenger; Up-Regulation | 2014 |